Ann: Positive Safety Data from Third Cohort of PI Clinical Trial, page-19

we are seeing the same play typical play as it happens everywhere with junior biotech.

we are now at a stage, where people with a higher risk profile (or have been able to reduce the risk...) have fully invested following sufficient DD that gives them the knowledge to understand the high chances of success.
the constant safety trial news just strengthens the notion that we have made the right choice. but we only add in small amounts, since we already have a large part of our targeted shares. hence, not really impacting the share price anymore.

the others simply don't have the guts and / or brains to take the decision to buy now or start buying yet. they are lurking around and hoping that it does not rise too much...some of those will be posting negatives to try to bring it down again, to compensate their lack of brains / guts with manipulating others instead.

its like the same old story when people keep asking you how you made so much money: you need to be able to take the difficult decisions when the majority is hesitant and make the first steps when everybody is backing down. few do it and jealousy eats them up....

biotech is a patience game with incomparable rewards should they succeed.